... A web-based Atlas of Patient-Derived Xenografts of cancer patients:A resource of MURAL PDX data



PDX model details

PDX ID 305R Cx
Host Strain(and Source) NSG
Source: Monash University
Host Strain Immune system Humanized NO
Host Type Castrate
Graft Site Subcutaneous
Current Generation
(* indicates number of generations grown in Castrate host)
45 (22*)
Average PDX Generation Time (days +/- SEM) 41 ± 1
Tumor preparation Tumor solid
Tumor Characterization Technology Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq
Tumor confirmed not to be of Mouse/EBV origin Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC
Passage QA performed Routine QA every 2-3 passages
Associated meta data
PDX model availability Yes (fixed, frozen or cryopreserved tissue)
Governance restriction for distribution Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements
Pubmed ID 34413304
Markers 305R Cx
AR N
PSA N
PSMA N
NE Y
ERG N
This heatmap displays the call type of curated CNVs in the presented samples.
This heatmap displays the call type of CNVs in commonly occurred samples.

PDX ID Gene Symbol CNV Log2 CNV Copy CNV Call Experiments name Platform Reference genome
305R Cx BRCA2 -0.990877 1.00634 loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
305R Cx CDH1 -0.96716 1.02302 loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
305R Cx CDKN1B -1.01054 0.992721 loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
305R Cx FANCA -0.96716 1.02302 loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
305R Cx KEAP1 0.526127 2.88012 gain MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
305R Cx MYC 3.1505 17.7593 gain-high MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
305R Cx PALB2 0.543608 2.91523 gain MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
305R Cx PIK3R2 0.526127 2.88012 gain MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
305R Cx PTEN -18.5159 0.00000534 homdel MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
305R Cx PTEN -0.938237 1.04374 loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
305R Cx RB1 -28.6876 0.00000000463 homdel MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
305R Cx RB1 -0.953166 1.033 loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
305R Cx SETD2 -0.903031 1.06952 loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
305R Cx SUFU -0.943499 1.03994 loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
305R Cx TP53 -0.93829 1.0437 loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
305R Cx USP7 0.543608 2.91523 gain MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
305R Cx ZFHX3 -0.96716 1.02302 loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19

Clinical Information

Sample Number 305R
Sample Site Prostate
Sample source Radical prostatectomy
Pathology Tumor Diagnosis Adenocarcinoma
Gleason Score 9
Primary Gleason Score 5
Secondary Gleason Score 4
Tertiary Gleason Score None
ISUP Grade Group 5
Tumor Grade pT3bN1
D'Amico Risk Classification 7
Tumor Volume (in cc) 73.4
Treatment Prior to Specimen Collection None

Patient Information

Patient Number 305
Sex Male
Diagnosis Prostate Cancer
PSA at diagnosis (ng/mL) 2
Consent to share data

Patient Tumor Collection (Current Model)
Tumour sample ID 305R
Patient Age (binned in 5 year age groups) 75-79
This heatmap displays the mutations of curated sequence variants.
Download The Mut plot is not shown
PDX ID Gene Symbol Depth ALT_FREQ Consequence Exon GnomAD_AF CADD_PHRED Clinvar_clnsig Platform Experiments Name Reference Library Type Instrument Type
305R Cx TP53 303 1.0 stop_gained '6/11 4.06E-06 36 Pathogenic Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500
305R Cx APC 580 0.53 missense_variant '16/16 . 22 - Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500
305R Cx HGF 436 0.51 missense_variant '18/18 . 24.4 - Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500
305R Cx MGAM 551 0.5 missense_variant '21/48 . 15.37 - Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500
305R Cx GRM7 668 0.48 missense_variant '8/10 . 24.3 - Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500
305R Cx DST 672 0.48 missense_variant '11/84 . 26.2 - Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500
305R Cx NF1 400 0.42 missense_variant,splice_region_variant '7/58 . 25.8 Uncertain_significance Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500

PDX ID Treatment1 Dose (mg/kg) Frequency Treatment2 Dose (mg/kg) Frequency Response
305R Cx Carboplatin 50 qwk NA NA NA Response
305R Cx Talazoparib 0.33 qd Carboplatin 50 qwk Response
305R Cx Talazoparib 0.33 qd NA NA NA No response